Related Experiment Video

Updated: Aug 18, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents

J E Tcheng1

  • 1Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.

American Heart Journal
|September 1, 1995
PubMed

Insights

Novel antithrombotic and antiplatelet agents, including direct thrombin inhibitors and glycoprotein IIb/IIIa inhibitors, show promise in reducing ischemic complications and restenosis after coronary revascularization. Careful heparin management may improve safety profiles.

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Ischemic complications and restenosis are significant risks following coronary revascularization.
  • Existing antithrombotic and antiplatelet therapies have limitations.

Purpose of the Study:

  • To review novel antithrombotic and antiplatelet agents for managing ischemic risks in coronary revascularization.
  • To evaluate the efficacy and safety of direct thrombin inhibitors and glycoprotein IIb/IIIa inhibitors.

Main Methods:

  • Review of recent clinical trials on direct thrombin inhibitors (hirudin, hirulog) and glycoprotein IIb/IIIa inhibitors (c7E3 Fab, Integrelin).
  • Analysis of efficacy in reducing ischemic events and restenosis.
  • Assessment of safety profiles, particularly bleeding risks associated with heparin.

Main Results:

  • Direct thrombin inhibitors offer predictable anticoagulation without increased bleeding compared to heparin.
  • Glycoprotein IIb/IIIa inhibitors, like c7E3 Fab and Integrelin, significantly reduce ischemic events when used with heparin.
  • Increased heparin-associated bleeding is a noted limitation.

Conclusions:

  • Novel antithrombotic and antiplatelet agents hold potential for improving outcomes in coronary revascularization.
  • Optimizing heparin dosage and patient management may enhance the safety of these agents.
  • Further trials are needed to define the definitive roles of these drugs in interventional cardiology.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...